94 related articles for article (PubMed ID: 26898077)
41. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
42. Stem cell origin of human myeloid blood cell neoplasms.
Fialkow PJ
Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
[TBL] [Abstract][Full Text] [Related]
43. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
44. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
45. Myeloperoxidase: a specific marker for myeloid cells in paraffin sections.
Pinkus GS; Pinkus JL
Mod Pathol; 1991 Nov; 4(6):733-41. PubMed ID: 1724087
[TBL] [Abstract][Full Text] [Related]
46. Lineage-specific clonality analysis of chronic myeloproliferative disorders and myelodysplastic syndrome by human androgen receptor assay.
Jáksó P; Kereskai L; Molnár L; Pajor L
Pathol Oncol Res; 2007; 13(2):114-22. PubMed ID: 17607372
[TBL] [Abstract][Full Text] [Related]
47. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
48. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.
De Silva P; Garaud S; Solinas C; de Wind A; Van den Eyden G; Jose V; Gu-Trantien C; Migliori E; Boisson A; Naveaux C; Duvillier H; Craciun L; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
EBioMedicine; 2019 Jan; 39():226-238. PubMed ID: 30579865
[TBL] [Abstract][Full Text] [Related]
49. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
50. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
51. FOXP1: a potential therapeutic target in cancer.
Koon HB; Ippolito GC; Banham AH; Tucker PW
Expert Opin Ther Targets; 2007 Jul; 11(7):955-65. PubMed ID: 17614763
[TBL] [Abstract][Full Text] [Related]
52. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract][Full Text] [Related]
53. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
54. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
55. The Role of β-Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical Study.
Geduk A; Atesoglu EB; Tarkun P; Mehtap O; Hacihanefioglu A; Demirsoy ET; Baydemir C
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):785-9. PubMed ID: 26422250
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis.
Xiao J; He B; Zou Y; Chen X; Lu X; Xie M; Li W; He S; You S; Chen Q
Sci Rep; 2016 Jul; 6():30437. PubMed ID: 27457567
[TBL] [Abstract][Full Text] [Related]
57. Erythroid proliferations in myeloid neoplasms.
Wang SA; Hasserjian RP
Hum Pathol; 2012 Feb; 43(2):153-64. PubMed ID: 22154053
[TBL] [Abstract][Full Text] [Related]
58. Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells.
Patzelt T; Keppler SJ; Gorka O; Thoene S; Wartewig T; Reth M; Förster I; Lang R; Buchner M; Ruland J
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):3120-3125. PubMed ID: 29507226
[TBL] [Abstract][Full Text] [Related]
59. Abnormal carbohydrate metabolism in patients with malignant blood dyscrasias.
Lisker SA; Brody JI; Beizer LH
Am J Med Sci; 1966 Sep; 252(3):282-8. PubMed ID: 5223180
[No Abstract] [Full Text] [Related]
60. Expression of cox-2, tie-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera.
Zetterberg E; Lundberg LG; Palmblad J
Br J Haematol; 2003 May; 121(3):497-9. PubMed ID: 12716375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
